Invesco
DMAC icon

Invesco’s DiaMedica Therapeutics DMAC Stock Holding History

Invesco’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$168K Buy
24,799
+6,171
+33% +$48.9K ﹤0.01% 3529
2025
Q4 		$148K Buy
18,628
+4,293
+30% +$32.1K ﹤0.01% 3592
2025
Q3 		$98.5K Buy
14,335
+450
+3% +$2.44K ﹤0.01% 3686
2025
Q2 		$54.2K Buy
+13,885
New +$54.1K ﹤0.01% 3719

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco's DMAC Position: Q1 2026 in Review

Invesco increased its DiaMedica Therapeutics (DMAC) stake by 33% in Q1 2026, buying an estimated $48.9K and bringing the position to 24,799 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #3529.

Invesco first reported a position in DMAC in Q2 2025 and has held it in 4 quarters since. 99 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Invesco held 24,799 shares of DiaMedica Therapeutics worth $168K as of Q1 2026.
  • Invesco bought 6,171 DiaMedica Therapeutics shares in Q1 2026, an estimated $48.9K.
  • DiaMedica Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3529 holding.
  • Invesco first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 99 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.